USP7 and AL amyloidosis: USP7 nitrothiophene-based inhibitor 5091 proved to be a promising therapeutic for treatment of multiple myeloma (Chauhan et al., 2012), and its second generation inhibitor, 217564, was determined to covalently modify C223 to inhibit USP7 activity (Wang et al., 2017).